528837-99-2

Basic information

• Product Name: 2,6-difluoro-4-[(3-methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carbonyl)-amino]-benzoic acid ethyl ester
• Synonyms: 2,6-difluoro-4-[(3-methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carbonyl)-amino]-benzoic acid ethyl ester
• CAS NO: 528837-99-2
• Molecular Weight: 445.506
• Mol File: 528837-99-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2,6-difluoro-4-[(3-methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carbonyl)-amino]-benzoic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-difluoro-4-[(3-methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carbonyl)-amino]-benzoic acid ethyl ester(528837-99-2)
• EPA Substance Registry System: 2,6-difluoro-4-[(3-methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carbonyl)-amino]-benzoic acid ethyl ester(528837-99-2)

Safety Data

• Hazardous Substances Data: 528837-99-2(Hazardous Substances Data)

Upstream product

• 203856-58-0 3-methoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene-2-carboxylic acid 
• 170100-73-9 2-bromo-3-methoxy-5,5,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene 
• 191469-36-0 ethyl 2,6-difluoro-4-aminobenzoate 

Downstream Products

• 365430-75-7 ethyl 2,6-difluoro-4-[(3-hydroxy-4-chloro-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carbonyl)-amino]-benzoate 
• 321995-62-4 2,6-difluoro-4-[(3-hydroxy-5,5,8,8,tetramethyl-5,6,7,8-tetrahydronaphthalene-2-carbonyl)-amino]-benzoic Acid 
• 365430-77-9 ethyl 2,6-difluoro-4-[(3-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carbonyl)-amino]-benzoate 

Relevant articles and documents

Synthesis and biological activity of retinoic acid receptor-α specific amides

Retinoids are analogues of all-trans-retinoic acid, a powerful hormone that mediates many fundamental biological processes. Cancer and other serious hyperproliferative diseases are attractive therapeutic targets for retinoids, but the therapeutic use of retinoids is limited due to severe toxicity. We report here the design of retinoid receptor-α specific ligands with growth inhibitory activity in breast cancer cell lines, and which do not cause the cutaneous toxicity associated with the currently available nonselective retinoid agonists.